Title |
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, April 2014
|
DOI | 10.1186/1745-6215-15-107 |
Pubmed ID | |
Authors |
Farsad Eskandary, Gregor Bond, Elisabeth Schwaiger, Zeljko Kikic, Christine Winzer, Markus Wahrmann, Lena Marinova, Helmuth Haslacher, Heinz Regele, Rainer Oberbauer, Georg A Böhmig |
Abstract |
Despite major advances in transplant medicine, improvements in long-term kidney allograft survival have not been commensurate with those observed shortly after transplantation. The formation of donor-specific antibodies (DSA) and ongoing antibody-mediated rejection (AMR) processes may critically contribute to late graft loss. However, appropriate treatment for late AMR has not yet been defined. There is accumulating evidence that the proteasome inhibitor bortezomib may substantially affect the function and integrity of alloantibody-secreting plasma cells. The impact of this agent on the course of late AMR has not so far been systematically investigated. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 1 | 1% |
Denmark | 1 | 1% |
Germany | 1 | 1% |
Unknown | 78 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 15% |
Student > Master | 10 | 12% |
Student > Bachelor | 10 | 12% |
Student > Ph. D. Student | 7 | 9% |
Student > Postgraduate | 6 | 7% |
Other | 16 | 20% |
Unknown | 20 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 39 | 48% |
Nursing and Health Professions | 4 | 5% |
Economics, Econometrics and Finance | 3 | 4% |
Immunology and Microbiology | 3 | 4% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 7 | 9% |
Unknown | 23 | 28% |